

Chimeric Antigen Receptor T-cell Therapy

sanskritiias.com/pt-cards/chimeric-antigen-receptor-t-cell-therapy-29

- The 4th June, 2021 was a historic day for Tata Memorial Hospital, IIT Bombay team and cancer care in India as the first CAR-T cell therapy (a type of gene therapy) was done. The CAR-T cells were designed and manufactured at Bioscience and Bioengineering (BSBE) department of IIT Bombay.
- The Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a breakthrough in cancer treatment. Clinical trials conducted globally have shown promising results in end stage patients, especially in patients suffering from Acute Lymphocytic Leukemia.
- Till now this technology was not available in India. CAR-T cell therapy costs 3-4 crore (INR). The manufacturing complexity is a major reason for the therapy cost. In order to promote and support development of CAR-T cell technology against cancer and other diseases, BIRAC and DBT have taken initiatives.
- The CAR-T cells were devloped with support from Biotechnology Industry Research Assistance Councilthrough National Biopharma Mission. BIRAC is a not-for-profit Section 8, Schedule B, Public Sector Enterprise, set up by Department of Biotechnology.

IAS / PCS **Online Video Course**

सामान्य_अध्ययन वैकल्पिक विषय (इतिहास एवं भूगोल)



IAS / PCS **Pendrive Course**

सामान्य अध्ययन

वैकल्पिक विषय (इतिहास एवं भूगोल)

15[%] Discount for Next 500 Students